Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Revenue: 2018-2024

Historic Revenue for Allogene Therapeutics (ALLO) over the last 5 years, with Dec 2024 value amounting to $22,000.

  • Allogene Therapeutics' Revenue fell 244.00% to -$344,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$843,000, marking a year-over-year decrease of 2308.57%. This contributed to the annual value of $22,000 for FY2024, which is 76.84% down from last year.
  • Allogene Therapeutics' Revenue amounted to $22,000 in FY2024, which was down 76.84% from $95,000 recorded in FY2023.
  • Allogene Therapeutics' Revenue's 5-year high stood at $114.1 million during FY2021, with a 5-year trough of $22,000 in FY2024.
  • In the last 3 years, Allogene Therapeutics' Revenue had a median value of $95,000 in 2023 and averaged $91,000.
  • Data for Allogene Therapeutics' Revenue shows a maximum YoY plummeted of 99.86% (in 2022) over the last 5 years.
  • Over the past 4 years, Allogene Therapeutics' Revenue (Yearly) stood at $114.1 million in 2021, then tumbled by 99.86% to $156,000 in 2022, then plummeted by 39.10% to $95,000 in 2023, then tumbled by 76.84% to $22,000 in 2024.